SABER

SABER College Opens Enrollment for Comprehensive Physical Therapist Assistant A.S. Degree Program

Retrieved on: 
Wednesday, March 27, 2024
SABER, PTA, Employment, Therapy, Health, Associate, Anatomy, Education, Patient, School, Pell Grant, Interview, Admission, Faculty, Student, Marketing, Mathematics, Curriculum, Workforce, Language, Physical, Nursing

MIAMI, March 27, 2024 /PRNewswire/ -- SABER College is pleased to announce the enrollment opening for its Physical Therapist Assistant (PTA) Associate of Science (A.S.) degree program .

Key Points: 
  • MIAMI, March 27, 2024 /PRNewswire/ -- SABER College is pleased to announce the enrollment opening for its Physical Therapist Assistant (PTA) Associate of Science (A.S.) degree program .
  • Delivered entirely in English, the Physical Therapist Assistant A.S. degree program at SABER College prepares students to enter the dynamic field of healthcare confidently.
  • "Our Physical Therapist Assistant program is a testament to SABER College's unwavering dedication to nurturing individuals' educational aspirations and fostering their evolution into conscientious contributors to society.
  • To be accepted into the Physical Therapist Assistant Program , applicants must meet the following requirements:
    Submission of a SABER college application, including a writing sample
    Attainment of a minimum score of 11.0 in mathematics, language, and reading on the TABE Test (Students with an A.A. degree or higher are exempt)
    For more information about the Physical Therapist Assistant A.S. degree program at SABER College and to begin your journey toward a rewarding healthcare career, visit www.sabercollege.edu or call (305) 443-9170.

Bridger Photonics Partners with Colorado State University to Advance Understanding of Methane Emissions Measurement via DOE Funding

Retrieved on: 
Tuesday, December 19, 2023
Oil, Gas, Data Management, Energy, Green Technology, Technology, University, Education, Environment, Environmental Health, Other Technology, Science, Software, Other Energy, Utilities, Research, Carbon, Lidar, Multimedia, SABER, Pennsylvania State University, DOE, CSU, Foreign policy, Colorado State University, GML, Methane

Bridger Photonics, Inc. (Bridger) announced today that it will be participating in a cutting-edge research project, with Colorado State University (CSU) as the lead investigator, to advance the understanding of methane emissions measurement and reporting.

Key Points: 
  • Bridger Photonics, Inc. (Bridger) announced today that it will be participating in a cutting-edge research project, with Colorado State University (CSU) as the lead investigator, to advance the understanding of methane emissions measurement and reporting.
  • CSU’s Energy Institute will oversee the project and utilize Bridger’s aerial LiDAR methane detection technology, Gas Mapping LiDAR™ (GML) to collect data.
  • The project will work with operators to measure emissions in the Denver-Julesburg and the Upper Green River basins.
  • The source resolved measurements will be compared to tower-based regional data collected by the Earth-Atmosphere Interactions Lab at Pennsylvania State University.

DURECT Corporation to Announce Third Quarter 2022 Financial Results and Provide Business Update on November 2

Retrieved on: 
Wednesday, October 26, 2022
U.S. Securities and Exchange Commission, SABER, AH, Risk, SEC, Regulation of tobacco by the U.S. Food and Drug Administration, Patient, Annual report, NASH, Technology, Private Securities Litigation Reform Act, Form 10-K, Food, Safety, DNA, Fatty liver disease, FDA, COVID-19, Chronic liver disease, Pharmaceutical industry

For more information aboutDURECT, please visit www.durect.com and follow us on Twitter https://twitter.com/DURECTCorp .

Key Points: 
  • For more information aboutDURECT, please visit www.durect.com and follow us on Twitter https://twitter.com/DURECTCorp .
  • Actual results may differ materially from those contained in the forward-looking statements contained in this press release, and reported results should not be considered as an indication of future performance.
  • These reports are available on our website www.durect.com under the "Investors" tab and on the SEC's website at www.sec.gov .
  • NOTE: POSIMIR is a trademark of Innocoll Pharmaceuticals Limited in the U.S. and a trademark of DURECT Corporation outside of the U.S. SABER is a trademark of DURECT Corporation.

AXWILL ELECTRICAL'S NEW CONDUIT FITTINGS RUNNING TO THE MARKET

Retrieved on: 
Wednesday, October 12, 2022
ISO, SABER, UL, BS, Aluminium, CNC, Electrical wiring

SHAOXING, China, Oct. 12, 2022 /PRNewswire/ -- Recently Zhejiang AXWILL ELECTRICAL COMPANY Limited has developed a new product line for junction box.

Key Points: 
  • SHAOXING, China, Oct. 12, 2022 /PRNewswire/ -- Recently Zhejiang AXWILL ELECTRICAL COMPANY Limited has developed a new product line for junction box.
  • In order to meet the requirements for Chile market and Peru market, AXWILL ELECTRICALalso made four new models for zinc die casting connector and couplings.
  • They are used to connect conduit and conduit, or connect conduit and junction boxes.
  • Now the aluminum and zinc die casting, steel punching machines, CNC machines, flexible conduit machines are all automatic.

Innocoll and DURECT Announce U.S. launch of POSIMIR®

Retrieved on: 
Monday, September 26, 2022
Central nervous system, Injection, Safety, Bradycardia, Achievement, Patient, U.S. Securities and Exchange Commission, Bupivacaine, Technology, C-reactive protein, Pain management, Annual report, Headache, AH, Risk, Fatty liver disease, COVID-19, Respiratory arrest, Methemoglobinemia, Sale, Food, Diarrhea, Vomiting, Anesthetic, Bruise, Surgeon, DNA, Nausea, SEC, Patent, Dizziness, Allergy, Coma, FDA, NASH, Association, Shoulder joint, Tinnitus, Paresthesia, Form 10-K, Chondrolysis, United States patent law, Somnolence, SABER, Constipation, Marketing, Itch, Blood, Incidence, Hypersensitivity, Elective surgery, Private Securities Litigation Reform Act, Regulation of tobacco by the U.S. Food and Drug Administration, Chronic liver disease, CNS, Anemia, Dentistry, Pharmaceutical industry, Vaccine, Fever, Dysuria, Dysgeusia, Hypoesthesia

"We are excited to bring a potential cornerstone of multi-modal post-operative pain management to surgeons with the launch of POSIMIR," said Louis Pascarella, Chief Executive Officer of Innocoll.

Key Points: 
  • "We are excited to bring a potential cornerstone of multi-modal post-operative pain management to surgeons with the launch of POSIMIR," said Louis Pascarella, Chief Executive Officer of Innocoll.
  • Per the terms of the collaboration between Innocoll and DURECT, Innocoll will make a $2 million payment to DURECT triggered by the first commercial sale of POSIMIR.
  • Previously, in August 2022, DURECT was issued a new patent by the US Patent Office, extending US patent coverage of POSIMIR to at least 2041, resulting in an $8 million milestone payment by Innocoll to DURECT.
  • NOTE: POSIMIR is a trademark of Innocoll Pharmaceuticals Limited in the U.S. and a trademark of DURECT Corporation outside of the U.S. SABER is a trademark of DURECT Corporation.

BAE Systems makes milestone delivery for inaugural EC-37B Compass Call

Retrieved on: 
Wednesday, September 21, 2022
Software, Other Defense, Contracts, Data Management, Technology, Defense, Security, Government Technology, Aerospace, Other Technology, Manufacturing, Military, Software, Department, Credit, BAE Systems, Compass, Technology, Interim, BAE, Lockheed EC-130H Compass Call, Atmosphere of Earth, SABER, Multimedia, Information, Radar, Weapon, Instrumentation

BAE Systems has designed, tested, and delivered key components for the U.S. Air Forces first EC-37B Compass Call aircraft.

Key Points: 
  • BAE Systems has designed, tested, and delivered key components for the U.S. Air Forces first EC-37B Compass Call aircraft.
  • (Credit: BAE Systems)
    Since the programs inception, BAE Systems has consistently delivered advanced capabilities for Compass Call, said Jared Belinsky, director of Electronic Attack Solutions at BAE Systems.
  • BAE Systems also recently successfully tested three third-party applications on Compass Calls Small Adaptive Bank of Electronic Resource (SABER) technology.
  • Work on Compass Call is being conducted at BAE Systems state-of-the-art facilities in Nashua, New Hampshire; Hudson, New Hampshire; and San Diego, California.

DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference

Retrieved on: 
Tuesday, September 6, 2022
Security (finance), COVID-19, Technology, Safety, SABER, AH, Form 10-Q, Risk, Fatty liver disease, Food, DNA, U.S. Securities and Exchange Commission, Chronic liver disease, Calendar, FDA, NASH, Annual report, Patient, Pharmaceutical industry

Management will also be available for virtual 1x1 meetings from September 12-14, 2022 during the conference.

Key Points: 
  • Management will also be available for virtual 1x1 meetings from September 12-14, 2022 during the conference.
  • If attendees would like to request a meeting, please contact H.C. Wainwright directly.
  • The 10-K and other public filings are available on our website www.durect.com under the "Investors" tab.
  • Food and Drug Administrationor other health authorities for any indication.

DURECT Corporation to Announce Second Quarter 2022 Financial Results and Provide Business Update on August 4

Retrieved on: 
Wednesday, July 27, 2022
DNA, AH, U.S. Securities and Exchange Commission, Food, Risk, Form 10-Q, NASH, Safety, COVID-19, Technology, FDA, SABER, Security (finance), Patient, Chronic liver disease, Fatty liver disease, Pharmaceutical industry

Larsucosterol (also known as DUR-928), DURECT's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes which are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients.

Key Points: 
  • Larsucosterol (also known as DUR-928), DURECT's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes which are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients.
  • For more information aboutDURECT, please visit www.durect.com and follow us on Twitter https://twitter.com/DURECTCorp .
  • Further information regarding these and other risks is included in DURECT's quarterly report on Form 10-Q filed on May 5, 2022 with the Securities and Exchange Commission under the heading "Risk Factors."
  • The 10-Q and other public filings are available on our website www.durect.com under the "Investors" tab.

DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer

Retrieved on: 
Tuesday, July 5, 2022
Evidence and efficacy of homeopathy, FDA, Wharton School of the University of Pennsylvania, NASH, Patient, KeyBank, Business, Mergers and acquisitions, Safety, Accounting, SABER, Investor Protection and Securities Reform Act of 2010, COVID-19, Fatty liver disease, U.S. Securities and Exchange Commission, MBA, Cowen, Risk, Food, Stifel, Arbutus Biopharma, Chronic liver disease, Technology, DNA, Treatment, SEC, AH, Duke University, Efficacy, Forward-looking statement, Pharmaceutical industry, Economics, Finance

CUPERTINO, Calif., July 5, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on epigenetic regulation to develop treatments for acute organ injury and chronic liver diseases, today announced the appointment ofTimothy M. Papp as its Chief Financial Officer.

Key Points: 
  • CUPERTINO, Calif., July 5, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on epigenetic regulation to develop treatments for acute organ injury and chronic liver diseases, today announced the appointment ofTimothy M. Papp as its Chief Financial Officer.
  • Papp will direct and oversee all financial and capital markets activities including accounting, financial reporting, financial planning and analysis, financial strategy, and investor relations.
  • "We are excited to welcomeTimto our executive leadership team, as he brings his deep understanding of corporate finance and corporate value drivers to DURECT," stated James E. Brown, D.V.M., President and Chief Executive Officer of DURECT.
  • Mr. Papp brings over 25 years of corporate finance experience to DURECT, including 15 years in the Biopharma sector.

Riiid and Latin American Education Leader Casa Grande introduce New AI-Powered Test Preparation Application for Colombia

Retrieved on: 
Thursday, June 30, 2022
Casa Grande, Arizona, CEO, USD, Conference on Neural Information Processing Systems, Research, Ministry of Science and ICT, SABER, Student, ICT, Friends, Ecosystem, Achievement Medal, Casa Grande High School, LAK, SAN, Partnership, AAAI, Technology, Learning, OE, Solution, Motivation, Creativity, Multimedia, Ministry, Education, Tutoring, Mobile phone, Medical device, Science, AI

SAN RAMON, Calif., June 30, 2022 /PRNewswire/ -- Riiid, a member of the Born2Global Centre and a leader in AI education solutions, and Casa Grande, a leading education company in Colombia and Puerto Rico, today introduced OE SABER, an artificial intelligence-powered mobile application designed to prepare students for SABER 11, the Colombian high-school exit exam with more than half a million annual test takers.

Key Points: 
  • "We are thrilled to enter into the Latin American market with a product that can help Colombian students prepare for their high-school exit exams," said YJ Jang, CEO of Riiid.
  • "Combined with Casa Grande's learning solutions, this new mobile app developed in cooperation with Riiid is a game changer for our youth, our school administrators, our communities, and the region," said Soraya M. Sesto, President of Casa Grande.
  • "It will help more students advance confidently to a post-secondary academic experience, further improving Colombia's competitiveness and future productivity in a global economy."
  • Response to the app was overwhelmingly positive from the 500 students who participated in a pilot program earlier this year.